Abstract
The discovery of endothelin (ET) in 1988 has led to considerable effort to unravel its implication in health and disease and the mechanisms evoked by ET. ET-1 and related signaling aberrancies are believed to be implicated in the pathogenesis of diverse cardiovascular diseases, such as hypertension, atherosclerosis, hypertrophy and diabetes. The endothelin system consists of three potent vasoconstrictive isopeptides, ET-1, ET-2 and ET-3, signaling through two G protein coupled receptors, ETA and ETB, which are linked to multiple signaling pathways. Activated signaling transduction pathways include the modulation of the adenylyl cyclase/cAMP pathway through stimulatory (Gs) and inhibitory (Gi) G proteins, activation of the phosphoinositide pathway through the activation of proteins Gq/11, generation of oxidative stress, growth factor receptor-related mitogenic events, such as the activation of phosphatidylinositol-3 kinase pathway, phosphoinositide pathway and activation of the mitogen-activated protein (MAP) kinase cascade. The levels of ETA and ETB receptors as well as the signaling pathways activated by these receptors are altered in several cardiovascular diseases including hypertension, hypertrophy, atherosclerosis, diabetes, etc. In this review, we provide an overview of the signaling events modulated by ET-1 in vascular smooth muscle cells in both physiological and pathological conditions.
Keywords: atherosclerosis, diabetes, hypertension, ETA/B receptors, ET-1, ET-1 signaling, ET-1 synthesis.
Current Vascular Pharmacology
Title:Endothelin-1 Signaling in Vascular Physiology and Pathophysiology
Volume: 12 Issue: 2
Author(s): Yessica-Haydee Gomez Sandoval, Mohammed Emehdi Atef, Louis-Olivier Levesque, Yuan Li and Madhu B. Anand-Srivastava
Affiliation:
Keywords: atherosclerosis, diabetes, hypertension, ETA/B receptors, ET-1, ET-1 signaling, ET-1 synthesis.
Abstract: The discovery of endothelin (ET) in 1988 has led to considerable effort to unravel its implication in health and disease and the mechanisms evoked by ET. ET-1 and related signaling aberrancies are believed to be implicated in the pathogenesis of diverse cardiovascular diseases, such as hypertension, atherosclerosis, hypertrophy and diabetes. The endothelin system consists of three potent vasoconstrictive isopeptides, ET-1, ET-2 and ET-3, signaling through two G protein coupled receptors, ETA and ETB, which are linked to multiple signaling pathways. Activated signaling transduction pathways include the modulation of the adenylyl cyclase/cAMP pathway through stimulatory (Gs) and inhibitory (Gi) G proteins, activation of the phosphoinositide pathway through the activation of proteins Gq/11, generation of oxidative stress, growth factor receptor-related mitogenic events, such as the activation of phosphatidylinositol-3 kinase pathway, phosphoinositide pathway and activation of the mitogen-activated protein (MAP) kinase cascade. The levels of ETA and ETB receptors as well as the signaling pathways activated by these receptors are altered in several cardiovascular diseases including hypertension, hypertrophy, atherosclerosis, diabetes, etc. In this review, we provide an overview of the signaling events modulated by ET-1 in vascular smooth muscle cells in both physiological and pathological conditions.
Export Options
About this article
Cite this article as:
Sandoval Gomez Yessica-Haydee, Atef Emehdi Mohammed, Levesque Louis-Olivier, Li Yuan and Anand-Srivastava B. Madhu, Endothelin-1 Signaling in Vascular Physiology and Pathophysiology, Current Vascular Pharmacology 2014; 12 (2) . https://dx.doi.org/10.2174/1570161112666140226122054
DOI https://dx.doi.org/10.2174/1570161112666140226122054 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nature and Nurture in the Early-Life Origins of Metabolic Syndrome
Current Pharmaceutical Biotechnology Efficacy and Adverse Effects of Venlafaxine in Children and Adolescents with ADHD: A Systematic Review of Non-controlled and Controlled Trials
Reviews on Recent Clinical Trials Autologous Adipose-Derived Regenerative Cells for Therapeutic Angiogenesis
Current Pharmaceutical Design Prediction of Bioactive Compounds Using Computed NMR Chemical Shifts
Combinatorial Chemistry & High Throughput Screening Editorial [Hot Topic:Genetic Disorders of Hemoglobin: Sickle Cell Anemia and Thalassemia (Guest Editors: Elliott Vichinsky, Griffin P. Rodgers and Eliezer Rachmilewitz)]
Current Molecular Medicine Editorial (Hot Topic: Update on Treatment Strategies in Patients with Non-alcoholic Fatty Liver Disease)
Current Pharmaceutical Design Effect of Heart Rate on Arterial Stiffness as Assessed by Pulse Wave Velocity
Current Hypertension Reviews Hallucinations Associated with Topiramate Therapy: A Case Report and Review of the Literature
Current Drug Safety New Pharmacological Approaches to the Prevention of Myocardial Ischemia- Reperfusion Injury
Current Drug Targets Effectiveness of Resveratrol Against Cardiovascular Disease
Mini-Reviews in Organic Chemistry Simulating Physiology and Methods for Therapeutic Evaluation with Emphasis on Hypertension
Current Topics in Medicinal Chemistry Healthy Properties of Garlic
Current Nutrition & Food Science Thromboxane Synthase Inhibitors and Thromboxane A2 Receptor Antagonists: A Quantitative Structure Activity Relationships (QSARs) Analysis
Current Medicinal Chemistry Association Between Adiposity Indices and Blood Pressure is Stronger in Sarcopenic Obese Women
Current Hypertension Reviews Anti-Diabetic Compounds and their Patent Information: An Update
Recent Patents on Inflammation & Allergy Drug Discovery Refining Genetic Approaches for Identifying Behavioral Loci
Current Genomics Xanthine Oxidase and its Role as Target in Cardiovascular Disease: Cardiovascular Protection by Enzyme Inhibition?
Current Pharmaceutical Design Rho-Kinase as a Drug Target for the Treatment of Airway Hyperresponsiveness in Asthma
Mini-Reviews in Medicinal Chemistry Oxidative Stress as a Regulator of Murine Atherosclerosis
Current Drug Targets Extracellular Hsp70: Export and Function
Current Protein & Peptide Science